AGC Biologics and Quell to progress Treg cell therapy development
The Milan Cell and Gene Center of Excellence at AGC Biologics will produce LVV material for Treg cell therapy candidates.
Cytiva Pipe dream to pipeline WP 3
FDA grants RMAT status to Opus Genetics’ OPGx-LCA5 gene therapy
Atsena closes $150m in Series C round to progress gene therapy
Alltrna plans to tackle rare diseases using tRNA-based therapies
Struggling bluebird bio to go private for less than $30m
Pfizer shelves haemophilia gene therapy Beqvez amid low demand
FDA grants fast track status to Rznomics’ RZ-001 for HCC
SmartCella gains rights to advance cell therapy research for Parkinson’s
